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Objective: To determine whether patients with clinically typical multifocal motor neuropathy (MMN)
with or without definite or probable conduction block (CB) differ in terms of clinical presentation,
immunological findings, or response to treatment with intravenous immunoglobulin (IVIg).
Methods: 23 consecutive patients were studied with the typical clinical features of MMN, consisting of
a progressive multineuropathic motor impairment with minimal or no sensory loss. In 14 patients, elec-
trophysiological studies disclosed the presence of a definite or probable CB according to the criteria
proposed by the American Association of Electrodiagnostic Medicine (AAEM) in at least one motor
nerve. Six patients had possible CB, defined as a degree of CB 10% less than that required by the
AAEM for probable CB, while no CB was detected in three patients.
Results: Patients with possible CB did not differ from those with a definite or probable CB in terms of
age at disease onset (mean 38.8 v 38.2 years, respectively), distribution and severity of limb
weakness, clinical impairment (mean Rankin score 2.2 in both), and frequency of antiganglioside anti-
bodies (33% v 29%). Patients with possible CB had a longer mean disease duration (9 v 5.9 years,
p < 0.05) and a less frequent consistent response to IVIg (67% v 86%) than those with a definite or
probable CB. Patients without a detectable CB had a similar frequency of antiganglioside antibodies
(33%) but had a longer disease duration (20.3 years), greater impairment (Rankin score 2.7), and
more frequent signs of axonal degeneration (41% of examined motor nerves) than patients with CB
(13–15%, p < 0.005). Only one patient without detectable CB (33%) consistently improved with IVIg.
Conclusions: Patients with possible CB were clinically and immunologically indistinguishable from
those with definite or probable CB, albeit with a slightly less frequent response to IVIg. This finding
suggests that failure to fulfil AAEM criteria for CB in patients with otherwise clinically typical MMN
should not preclude this diagnosis and consequently a treatment trial with IVIg. Whether the longer
duration and greater severity of the disease and more frequent axonal impairment in patients without
detectable CB than in those with CB explain their lower response to IVIg remains to be established.
Multifocal motor neuropathy (MMN) is a recently iden-tified disorder characterised by progressive asymmet-ric limb weakness, minimal or no sensory impair-
ment, and persistent multifocal partial conduction blocks
(CB) in motor but not sensory nerves.1–4 CB has been defined
as a reduction in the amplitude or area (or both) of the com-
pound muscle action potential (CMAP) obtained by proximal
versus distal stimulation of motor nerves in the absence of
abnormal temporal dispersion. The degree that this reduction
has to attain to be significant for CB in MMN varies, however,
from author to author, ranging from 20% to over 50%.3
Recently the American Association of Electrodiagnostic Medi-
cine (AAEM) proposed criteria for the diagnosis of definite
and probable partial CB in MMN.5 While the use of these
stringent criteria (see Methods section) may help to
distinguish true CB from the reduction of CMAP amplitude
sometimes observed in chronic demyelination and chronic
axonal loss,6–8 it carries the risk of underestimating the
presence of CB in the early phases of the disease and may
delay the diagnosis of a potentially treatable disease.9
Moreover, some patients with clinically typical MMN have no
detectable CB, leading some to question whether CB should be
a mandatory criterion for the diagnosis of MMN.10 11 It is
uncertain whether patients with clinically typical MMN who
either have no CB or have CB not fulfilling the AAEM criteria
differ in terms of clinical presentation, immunological
findings, or response to treatment from those with definite or
probable CB as defined by the AAEM criteria.12 13
METHODS
Patients
We studied 23 consecutive patients with clinically typical
MMN examined in our department from July 1990 through
September 1999 (table 1). The clinical diagnosis of MMN was
based on the presence of (a) chronic or stepwise progressive
asymmetric limb weakness with a multineuropathic distribu-
tion affecting the muscles of at least two distinct motor nerves
and lasting at least two months; and (b) minimal or no
sensory loss or symptoms and absence of clinical signs of
upper motor neurone involvement.
Clinical evaluation
We directly examined all patients and collected or evaluated
the following data at the time of the first neurological inves-
tigation: name, age, sex, age at onset, type of neuropathy
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Table 1 Motor nerve conduction studies and response to IVIg in patients with multifocal motor neuropathy
Patient
Age at
onset
(years) Sex
Duration of
disease at first
visit (years)
Motor nerve conduction studies
Response to IVIg (before→after IVIg)
Antiganglioside
titres*
Total
nerves
tested
Nerves with CB (% of CB) Nerves with possible
axonal degeneration
(dCMAP)Definite (AAEM) Probable (AAEM) Possible Rankin ULDS LLDS
1 62 M 11 4 MCN L (56%) UN R (85%)†,
UN L (43%)‡
UN R (2.6) PN R (0.7),
PN L (NR)
3→2 3→2 1→0 0
2 39 M 9 7 UN L (92%), MN R (61%) UN R (45%), MN L
(58%)‡
UN R (0.1) 2→1 3→2 2→1 GM1 (1/640)
3 30 M 4 8 MN R (76%) UN R (46%)‡,
TN L (50%)†
UN L (2.8) 2→2 3→2 1→0 GD1a (1/5120 IgG)
4 21 F 5 8 UN R (93%), UN L (87%)
MN R (60%), MN L
(80%), PN L (60%)
RN L (NR), UN L (2.8),
MN L (1.5)
3→1 3→2 2→0 0
5 47 F 4 7 MN R (62%) UN R (42%) MN L (41%)‡ None 2→1 1→0 2→2 0
6 53 M 19 10 TN R (81%) UN R (54%)†,
UN L (66%)†,
MN L (60%)†,
RN L (40%)†
MN R (0.2), UN R
(1.8), PN R (0.4), TN L
(0.1)
2→2 2→2 2→2 0 (IgM M protein)
7 25 F 1 5 MN L (50%) UN L (0.5) 2→1 2→1 0→0 GM1 (1/640)
8 28 M 4 7 UN R (70%), UN L (99%),
MN R (88%), MN L
(93%), TN R (64%), PN R
(52%)
None 3→3 3→3 2→2 0
9 48 M 3 10 RN R (58%), RN L (93%),
UN R (53%), TN L (96%)
PN L (0.8) 2→1 2→0 2→2 0
10 43 M 8 6 MN R (89%) UN R (39%) None 2→1 3→2 0→0 0
11 36 M 4 10 MN L (96%) UN R (61%)† None 2→0 2→0 0→0 0
12 40 M 0.25 8 UN R (50%) UN L (46%) None 2→0 2→0 2→0 GD1a (1/1280)
13 29 M 0.25 6 UN L (52%) RN L (36%) None 2→1 2→1 2→0 0
14 34 M 10 6 MN R (40%) MN L (42%)† UN L (NR) 2→1 3→2 0→0 0
15 25 F 25 8 MN L (39%) UN L (0.6 V) 2→1 2→2 0→0 0 (IgM M protein)
16 24 F 12 10 UN R (35%) None 2→2 2→2 2→2 0
17 46 M 2 6 UN L (37%) UN L (2.7), PN R (0.9),
PN L (1.3)
2→1 2→0 2→1 GD1a (1/640), GM2
(1/327 680)
18 50 F 10 8 RN R (40%)† None 3→2 3→2 2→0 0
19 35 M 1 6 UN R (34%),
MN R (55%)†,
MN L (44%)†
None 1→1 2→1 2→1 GM1 (1/81 980),
GD1a (1/10 240)
20 53 M 4 9 TN R (65%)†,
TN L (43%)
PN R (NR), RN L (NR) 3→3 3→3 3→3 0
21 39 F 25 8 UN L (0.5), MN R (NR),
MN L (NR)
3→3 3→3 0→0 GM1 (1/640)
22 46 F 20 6 UN R (0.4), UN L (0.6),
MN R (NR), MN L (NR)
3→3 3→3 0→0 0
23 57 F 16 3 None 2→2 2→2 0→0 0
*IgM unless otherwise specified; †moderate temporal dispersion; ‡severe temporal dispersion. AAEM, American Association of Electrodiagnostic Medicine criteria; CB, conduction block; dCMAP, distal compound muscle action
potential (mV); F, female; IVIg, high dose intravenous immunoglobulin treatment; L, left; LLDS, lower limb disability score; M, male; MCN, musculocutaneous nerve; MN, median nerve; NR, no response; PN, peroneal nerve; R, right;
RN, radial nerve; TN, tibialis posterior nerve; ULDS, upper limb disability score; UN, ulnar nerve.
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symptoms and their duration, type of progression (chronic
progressive, stepwise, remitting), number and type of
clinically affected motor nerves, predominant distribution of
weakness (proximal versus distal, upper versus lower limbs),
and presence, severity, and distribution of sensory symptoms
and signs. Severity of the neuropathy was scored according to
the following scales. (1) The Medical Research Council rating
scale measures muscle strength in the 20 most affected mus-
cles of the upper and lower limbs (maximal score of 100). (2)
The modified Rankin disability scale14 scores 0 as no
symptoms; 1 as non-disabling symptoms not interfering with
lifestyle; 2 as minor disability leading to some restriction of
lifestyle but with the patient retaining the ability to look after
himself or herself; 3 as moderate disability significantly
interfering with lifestyle or preventing fully independent
existence; 4 as moderately severe disability preventing
independent existence, although with the patient not in need
of constant attention day and night; and 5 as total
dependence, requiring constant attention day and night. (3)
The functional impairment scales for upper and lower
limbs14 score 0 as no symptoms; 1 as upper and lower limb
symptoms without functional impairment (normal walk); 2
as some minor difficulties in manual activities or abnormal
walking without support; 3 as inability to perform some
manual activities or the ability to walk independently with
support; 4 as inability to perform manual tasks or the need
for help with walking; and 5 as total paralysis or being
confined to a wheelchair.
Nerve conduction studies
In all patients nerve conduction studies were performed as
reported previously14 in at least four motor nerves (range 4–10,
mean 7.2) and two sensory nerves (range 2–7, mean 4.6)
before any treatment and yearly during follow up. Motor CB
was classified according to AAEM criteria5 as follows: (a) defi-
nite: presence of at least 50% or 60% reduction of proximal
versus distal CMAP amplitude in the nerves of the upper and
lower limbs, respectively, with minimal temporal dispersion
(< 30% increased CMAP duration); (b) probable: presence of
either at least 40% or 50% reduction of proximal versus distal
CMAP amplitude in the nerves of the upper and lower limbs,
respectively, with minimal temporal dispersion (see above) or
at least 50% or 60% reduction of proximal versus distal CMAP
amplitude in the nerves of the upper and lower limbs, respec-
tively, with moderate temporal dispersion (31% to 60%
increased CMAP duration).
In addition we defined possible CB as the presence of (a) at
least 30% or 40% reduction of proximal versus distal CMAP
amplitude in the nerves of the upper and lower limbs, respec-
tively, with minimal temporal dispersion (see above), (b) at
least 40% or 50% reduction of proximal versus distal CMAP
amplitude in the nerves of the upper and lower limbs, respec-
tively, with moderate temporal dispersion (see above), or (c) at
least 50% or 60% reduction of proximal versus distal CMAP
amplitude in the nerves of the upper and lower limbs, respec-
tively, with severe temporal dispersion (> 60% increased
CMAP duration).
Finally, no overt CB was defined as the presence of a lesser
degree of CMAP amplitude reduction or the absence thereof.
In all patients the following electrophysiological parameters
were also analysed: (a) the number of motor nerves with other
features of demyelination: > 30% reduction of motor conduc-
tion velocities below the lower normal limits and > 50%
increase of F wave and distal latencies above the upper normal
limits when the distal CMAP amplitude was < 80% of the
lower normal limits, or > 20% reduction of motor conduction
velocities below the lower limit of normal and > 20% or
> 25% increase of F wave or distal latencies, respectively,
above the upper limit of normal when the distal CMAP ampli-
tude was > 80% of the lower normal limit15; (b) the number of
motor nerves with possible signs of axonal degeneration,
defined as the presence of 50% or more reduction of distal
CMAP amplitude below the lower normal limits (nerves in
which no motor response could be elicited were included in
this category) associated with a neurogenic pattern on needle
electromyography of corresponding muscle; and (c) the
number of sensory nerves with reduced amplitudes or delayed
latencies of sensory nerve action potentials.
Immunological studies
In all patients anti-GM1, anti-GM2 and anti-GD1a IgG and
IgM antibodies were measured by enzyme linked immuno-
sorbent assay (ELISA) before treatment according to a previ-
ously reported standard ELISA procedure.16 In all patients the
presence of monoclonal gammopathy was investigated by
standard agarose gel serum electrophoresis and characterised
by immunofixation. Cerebrospinal fluid was examined in 18
patients for total protein concentration and cell count by
standard procedures.
Assessment of response to intravenous
immunoglobulin treatment
All patients were treated with intravenous immunoglobulin
(IVIg) (Ig Vena, Farma Biagini, now Kedrion, Castelvecchio
Pascoli, Italy or Sandoglobulin, Sandoz, Basel, Switzerland) at
the initial standard dose of 2 g/kg over four or five consecutive
days, followed by periodic maintenance IVIg infusions at a dose
of 1–1.2 g/kg over two or three consecutive days at the time of
clinical worsening. Response to IVIg treatment was assessed in
all patients 8–10 days after each of the initial two or three IVIg
courses and classified as follows:( a) consistent, with improve-
ment by at least one point in the Rankin disability or in the
upper or lower limb impairment scores, or of at least 20% in the
upper or lower limb MRC sumscores; or (b) marginal, with
improvement by at least 10% in the upper or lower limb MRC
sumscores without changes in disability or impairment scores.
Patients were subsequently examined during follow up initially
every month then every two to three months before IVIg infu-
sions. To decrease the frequency of IVIg infusions, oral
cyclophosphamide was added for 12 patients at some time dur-
ing the follow up for one to three years at a daily dose of
1.5–2 mg/kg and was subsequently adjusted (range 0.5–3 mg/
kg/day) tomaintain thewhite blood cell count between 3×109/l
and 3.5 × 109/l.3 17 One of these patients also received
azathioprine and chlorambucil for at least six months each dur-
ing follow up while another patient with an IgM monoclonal
gammopathy had been treated for three years with chloram-
bucil 2.5–5 mg/day before starting IVIg.
RESULTS
Clinical features
With few exceptions, all patients fulfilled the clinical diagnos-
tic criteria for MMN recently proposed for use in randomised
trials.18 The only exceptions were disease duration at the time
of the first visit at three months in two patients (patients 12
and 13, table 1); predominant lower limb involvement in three
patients (patients 5, 9, and 17); proportional upper and lower
limb impairment in five patients (patients 6, 12, 13, 19, and
20); and mild sensory signs in two patients (patients 8 and
18). None of these findings was deemed sufficient to exclude
the clinical diagnosis of MMN.
In 14 of the 23 patients with clinically typical MMN
(patients 1–14, table 1), nerve conduction studies found the
presence of definite or probable CB according to the AAEM
criteria in at least onemotor nerve,while six patients (patients
15–20) had a possible CB in at least one motor nerve. In three
patients (patients 21–23), no overt CB was detected in the
motor nerves examined, although they all had some, usually
minor, electrophysiological features consistent with segmen-
tal demyelination. In one (patient 21) no motor response was
IVIg treatment of multifocal motor neuropathy 763
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evoked from both median nerves and moderately reduced
motor conduction velocities (36 m/s) with notably decreased
CMAP amplitudes (0.5 mV) were obtained by proximal and
distal stimulation of the left ulnar nerve. In this patient
normal proximal and distal CMAP amplitudes (12.1 and
12.6 mV, respectively) with normal motor conduction veloci-
ties (58 m/s) were registered from the slightly affected right
ulnar nerve. The second patient (patient 22) had notably
decreased (< 1 mV) proximal and distal CMAP amplitudes in
both ulnar motor nerves with notably reduced motor conduc-
tion velocities (22.8 m/s) on the right and marginally reduced
motor conduction velocities on the left ulnar nerve (46 m/s).
No motor response was evoked from both median nerves in
the second patient. The third patient (patient 23) had 20%
reduction of proximal versus distal CMAP amplitude without
temporal dispersion in the right ulnar nerve, evolving after
IVIg into 8% CMAP reduction without temporal dispersion.
Table 2 summarises the clinical features of patients with typi-
cal MMN, recorded at their first visit, according to the presence
and degree of CB. Patients with definite or probable CB did not
differ from patients with possible CB in terms of age at disease
onset, distribution of weakness, progression and severity of the
disease, and frequency of sensory loss, yet the latter had a
significantly longer mean disease duration (9 v 5.9 years,
p < 0.05 by Student’s t test). Patients without overt CB were
much older than patients with CB, mostly reflecting a longer
disease duration. The former had all been affected formore than
15 years, while only two patients with CB had a similar disease
duration (table 1). Patients without overt CB tended to be more
severely affected than patients with CB, although in all of them,
weakness was restricted to the upper limbs. Minor sensory loss
was found in only 1 of the 14 patients (7%) with definite or
probable CB and in 1 of 6 (17%) with possible CB.
Electrophysiological features
Table 1 summarises the results of motor nerve conduction
studies in patients with typical MMN. Only one patient with
definite or probable CB had CB in a single motor nerve (range
1–6 nerves with CB/patient, mean 3.1) compared with four
patients with possible CB (range 1–3, mean 1.5). In both
groups, CB was more frequently detected in upper limb
nerves. The distribution of nerves with CB did not differ
between the two groups. Other features of demyelination (see
Methods) were observed in a similar proportion of examined
motor nerves in patients with definite or probable (9%), possi-
ble (4%), or no overt CB (6%) and were confined in all but two
nerves to a nerve with CB. No significant difference in the
proportion of patients with these abnormalities was observed
between the three groups (50%, 17%, and 33%). Signs of pos-
sible axonal degeneration (table 1) were found in a similar
proportion of patients with definite or probable (57%), possi-
ble (50%), or no overt CB (67%), yet the proportion of motor
nerves with signs of possible axonal degeneration was signifi-
cantly higher in those without (41%) than in those with defi-
nite or probable (15%) or possible CB (13%, p < 0.005 by χ2
test). A reduction of sensory nerve action potential amplitude
was found in a small proportion of sensory nerves examined
in all three patient groups (2 of 59, 3%; 4 of 32, 12%; 1 of 14,
7%, respectively). Only one patient with possible CB (patient
18) had a reduction of the sensory nerve action potential
amplitude to < 50% of the lower normal limit in one radial
nerve.
Laboratory and immunological findings
High titres of antibodies to the ganglioside GM1, GD1a or
GM2 (> 1/320) were found in four patients (29%) with defi-
nite or probable CB, in two patients (33%) with possible CB,
and in one patient (33%) without overt CB (table 1). Cerebro-
spinal fluid protein was mildly increased in four of 11 patients
(36%) with definite or probable CB (range 54–86 mg/dl), in
one of five patients (20%) with possible CB (80 mg/dl) and in
none of two patients without overt CB. One patient in the
group with definite or probable CB (7%) and one patient with
possible CB (17%) had an IgM monoclonal gammopathy of
undetermined significance.
Response to IVIg treatment
The clinical responses to IVIg are reported for each patient in
table 1 and are grouped in table 3 according to the presence
Table 2 Clinical features of patients with clinically typical multifocal motor neuropathy in relation to the presence and
degree of motor CB
Patients with definite or probable CB
(AAEM criteria)
Patients with
possible CB
Patients without
overt CB
Number of patients 14 6 3
Men/women 11/3 3/3 0/3
Mean age at onset, years (range) 38.2 (21–62) 38.8 (24–53) 47.3 (39–57)
Mean age at first visit, years (range) 44.1 (26–73) 47.8 (36–60) 67.7 (64–73)
Mean disease duration at first visit, years (range) 5.9* (0.3–19)† 9* (1–25)† 20.3 (16–25)
Type of progression (chronic progressive/stepwise) 3/11 2/4 1/2
Limb weakness distribution
UL>/=/<LL 9/3/2 3/2/1 3/0/0
Asymmetric/symmetric 13/1 6/0 3/0
Mean scores
Rankin score 2.2 2.2 2.7
UL/LL impairment score 2.4/1.3 2.3/1.8 2.7/0
UL/LL MRC sumscore 75.8/88.3 79.5/83.3 57.3/96.3
UL motor nerves clinically affected
Total 56 17 18
Ulnar 25 8 6
Median 16 4 5
Radial 14 5 5
Musculocutaneous 1 – 2
LL motor nerves clinically affected
Total 17 11 –
Peroneal 10 7 –
Tibial 3 4 –
Femoral 4 – –
Mean number of affected nerves/patient (range) 5.2 (2–8) 4.7 (3–6) 6 (4–7)
Number of patients with mild sensory impairment 1 (7%) 1 (17%) 0 (0%)
*p<0.05 by Student’s t test; †one patient had a duration of >15 years. LL, lower limb; MRC, Medical Research Council; UL, upper limb.
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and degree of motor CB. Twelve patients with definite or prob-
able CB (86%) and four patients with possible CB (67%) con-
sistently improved after IVIg treatment, while an additional
patient in both groups improved marginally (total patients
improved 93% and 83%, respectively). The mean improvement
in the Rankin, upper limb impairment, and MRC scores was
also higher in patients with definite or probable than in those
with possible CB but the difference was not significant. A con-
sistent improvement in the upper limb MRC sumscore (27%)
but not in the Rankin and limb impairment scores was
observed after IVIg treatment in one patient without overt CB
(patient 21). Another patient in this group (patient 22) had
only slight improvement (7%) in the upper limb MRC
sumscore; nonetheless, she reported a consistent improve-
ment in her upper limb strength. Even though oral cyclophos-
phamide in some patients reduced the frequency of mainte-
nance IVIg infusions,17 it did not seem to affect the degree of
response to IVIg; however, this aspect was not specifically
addressed.
DISCUSSION
Since the original descriptions of MMN,19 20 more than 300
patients with the disease have been reported on.3 In almost all
these patients the presence of CB was considered a “condicio
sine qua non” for the diagnosis of MMN despite some
disagreements among authors on the degree of CB considered
to be required for MMN. Therefore, the AAEM has proposed a
set of criteria for the definition of definite and probable CB.5
Application of these relatively stringent criteria is probably
useful for the inclusion of patients in treatment trials but it
risks underestimation of the presence of CB in the early
phases of the disease. This was clearly exemplified by one of
our patients (patient 8), who initially presented with a 24%
reduction of proximal versus distal CMAP amplitude without
temporal dispersion in the right ulnar and median nerves. Two
years later, as the patient became more severely affected, this
increased to 70% and 88%, respectively.9 In other patients
typical CB may decrease or even disappear in some nerves
after several years of the disease because of a progressive
reduction of the distal CMAP amplitude,12 which may reflect
either secondary axonal degeneration or the appearance of
unrecognised very distal CB. These early or late features of CB,
together with possible but often not observed very proximal or
very distal CB, have been invoked as a possible explanation for
the absence of CB in some patients with clinically typical
MMN.10 11 Indirectly this hypothesis was supported in some of
these patients by the same anti-GM1 antibody reactivity and
response to immune therapies, particularly IVIg, as was
observed in MMN.1 14 16 21–25 Therefore, some authors have
questioned whether the presence of CB should be considered
a mandatory criteria for the diagnosis of MMN for patients
with otherwise typical clinical presentation.10 11 In some of
these patients “without” CB, a lesser degree of amplitude
reduction than those required by the current diagnostic crite-
ria were present, while in others no evidence of CB was
found.10 11
In this study we studied the clinical and immunological
features and the response to immune therapy in relation to the
presence and degree of motor CB in 23 patients with the typi-
cal clinical presentation of MMN. Fourteen of these patients
had definite or probable CB according to AAEM criteria, six
had possible CB defined as a 10% lesser degree of CMAP
reduction than that required by AAEM for probable CB, and
three had no evidence of CB according to these criteria. In
accordance with a recently reported series of MMN patients
with variable degrees of CB,12 patients with possible CB were
clinically and immunologically indistinguishable from those
with probable or definite CB in terms of age of onset, progres-
sion, distribution and severity of limb weakness, and
frequency of antiganglioside antibodies. In addition in our
study over 80% of patients in both groups responded to IVIg,
although improvement tended to be less pronounced and less
frequent in patients with possible than in those with probable
or definite CB, possibly reflecting their longer disease duration
at the time of the initial treatment.13 On the other hand,
patients without CB had a similar frequency of antiganglio-
side antibodies but, at the time of our first evaluation, they
were older, had a longer duration and greater severity of the
disease, and had more frequent signs of possible axonal
impairment than patients with CB.While the latter difference
may theoretically explain their less frequent and less intense
response to IVIg, the limited number of patients in this group
does not permit drawing definite conclusions. Similar findings
were recently reported in a prospective study of 37 patients
with a lower motor neurone disorder and electrophysiological
evidence of CB or other features compatible with segmental
demyelination.13 Although the inclusion criteria in that study
did not specify a multineuropathic distribution of the motor
deficits, thus possibly explaining why almost 20% of patients
proved to have motor neurone disease at follow up, 70% of
patients with definite or probable CB according to AAEM cri-
teria responded to IVIg (84% in our series) compared with
50% of those without CB (56% in our series). These figures
varied in relation to applied criteria of defined CB. Still, a vari-
able proportion of patients not fulfilling any of these criteria
responded to IVIg, while among patients with CB, lack of
response to IVIg was often associated with long disease dura-
tion. The results of that and of the present study lend support
to the opinion10–12 that the failure to fulfil the criteria for defi-
nite or probable CB proposed by the AAEM, in a patient with
otherwise clinically typical MMN, should not preclude this
Table 3 Response to IVIg treatment in patients with multifocal motor neuropathy in relation to the presence and degree
of motor CB
Patients with definite or
probable CB (AAEM
criteria) Patients with possible CB
Patients without overt
CB
Number of patients treated 14 6 3
Number that consistently improved 12 (86%) 4 (67%) 1 (33%)
In Rankin score 11 3 0
Mean Rankin scores before → after IVIg 2.2→1.2 2.2→1.7 2.7→2.7
In UL impairment score 12 3 0
Mean score before → after IVIg 2.4→1.4 2.3→1.7 2.7→2.7
In LL impairment score 6 3 –
Mean score before → after IVIg 1.3→0.6 1.8→1.2 0→0
By 20% in UL or LL MRC score 5 1 1
Mean UL MRC score before → after IVIg 75.8→87.3 79.5→88.5 57.3→63
Mean LL MRC score before → after IVIg 88.3→95.5 83.3→89.3 96.3→98.7
Number that marginally improved >10% in UL or LL MRC score 1 (7%) 1 (17%) 0
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diagnosis and consequently a treatment trial with IVIg. In
addition the consistent improvement after IVIg observed in
one of our patients without CB and the subjective improve-
ment reported by another patient suggested that multineuro-
pathic presentation of a lower motor neurone disorder should
alert the investigator to a potentially treatable motor
neuropathy despite the absence of CB, particularly in patients
with a long disease duration.
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